
There has been a lot of research on Alzheimer’s and dementia that has been released over the summer. I wrote about the POINTER study, which found that lifestyle interventions can have a positive impact on cognitive health.
A team from the Alzheimer’s Prevention Registry attended the 2025 Alzheimer’s Association International Conference in Toronto in July, where the POINTER findings were discussed among other promising research. The team shared their top takeaways from the conference.
One development that I’m excited about is blood biomarkers, which may facilitate the Alzheimer’s diagnostic process. Blood tests that can be performed on existing medical equipment and reduce the need for expensive and time-consuming PET scans could catch the disease in earlier stages, when current treatments on the market work the best.
Speaking of treatments, some researchers are taking seriously the increased risk of brain bleeds in the latest crop of Alzheimer’s drugs. Scientists are focusing on new technology that could deliver lower doses of drugs that can safely cross the blood-brain barrier. I’ve written about Leqembi, which has seen slow uptake despite being fully approved by the FDA. One of the concerning factors about the drug is the increased risk of brain swelling and bleeding. While the Alzheimer’s community is desperate for new and effective treatments, serious side effects shouldn’t be overlooked.
There’s also new research looking at the role of the immune system and gut microbiome in regards to Alzheimer’s risk. I will definitely be following developments in this area, as I believe that Alzheimer’s and other dementias are not merely brain diseases and require a holistic treatment approach.
Illustration created by Google Gemini.








![Pageflex Persona [document: PRS0000038_00069]](https://memoriesproject.files.wordpress.com/2014/02/reluctant-caregiver-cover.jpg)





